Anti-dengue Vaccine

Sanofi India shares advanced nearly 5 per cent to hit intraday high of Rs 4,450 after the Mexican government approved the world's first anti-dengue vaccine developed by France-based Sanofi Pasteur which is an arm of the India-listed Sanofi India.

At a time when India is struggling with rising number of dengue cases with each passing year, the Mexican government has approved the world's first anti-dengue vaccine which is designed to protect people in the 9-45 age group from nine to 45 years from all four subtypes of the virus.

At a time when India is struggling with rising number of dengue cases with each passing year, the Mexican government has approved the world's first anti-dengue vaccine which is designed to protect people in the 9-45 age group from nine to 45 years from all four subtypes of the virus.

Sanofi India shares advanced nearly 5 per cent to hit intraday high of Rs 4,450 after the Mexican government approved the world's first anti-dengue vaccine developed by France-based Sanofi Pasteur which is an arm of the India-listed Sanofi India.

At a time when India is struggling with rising number of dengue cases with each passing year, the Mexican government has approved the world's first anti-dengue vaccine which is designed to protect people in the 9-45 age group from nine to 45 years from all four subtypes of the virus.

At a time when India is struggling with rising number of dengue cases with each passing year, the Mexican government has approved the world's first anti-dengue vaccine which is designed to protect people in the 9-45 age group from nine to 45 years from all four subtypes of the virus.